These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 36975369

  • 1. Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study.
    Murata S, Oshima N, Iwasa T, Fukao Y, Sawata M.
    Antibodies (Basel); 2023 Mar 10; 12(1):. PubMed ID: 36975369
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
    Langley JM, Gantt S, Halperin SA, Ward B, McNeil S, Ye L, Cai Y, Smith B, Anderson DE, Mitoma FD.
    Vaccine; 2024 Jan 25; 42(3):713-722. PubMed ID: 38142214
    [Abstract] [Full Text] [Related]

  • 6. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
    Essink B, Chu L, Seger W, Barranco E, Le Cam N, Bennett H, Faughnan V, Pajon R, Paila YD, Bollman B, Wang S, Dooley J, Kalidindi S, Leav B.
    Lancet Infect Dis; 2023 May 25; 23(5):621-633. PubMed ID: 36682364
    [Abstract] [Full Text] [Related]

  • 7. Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18-60 and 60+ Age Cohorts.
    Gordeychuk IV, Kozlovskaya LI, Siniugina AA, Yagovkina NV, Kuzubov VI, Zakharov KA, Volok VP, Dodina MS, Gmyl LV, Korotina NA, Theodorovich RD, Ulitina YI, Vovk DI, Alikova MV, Kataeva AA, Kalenskaya AV, Solovjeva IV, Tivanova EV, Kondrasheva LY, Ploskireva AA, Akimkin VG, Subbotina KA, Ignatyev GM, Korduban AK, Shustova EY, Bayurova EO, Zhitkevich AS, Avdoshina DV, Piniaeva AN, Kovpak AA, Antonova LP, Rogova YV, Shishova AA, Ivin YY, Sotskova SE, Chernov KA, Ipatova EG, Korduban EA, Ishmukhametov AA.
    Viruses; 2023 Aug 29; 15(9):. PubMed ID: 37766235
    [Abstract] [Full Text] [Related]

  • 8. Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine.
    Cox KS, Zhang L, Freed DC, Tang A, Zhang S, Zhou Y, Wang IM, Rupp RE, Adler SP, Musey LK, Wang D, Vora KA, Fu TM.
    J Infect Dis; 2021 Jun 04; 223(11):2001-2012. PubMed ID: 33031517
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers.
    Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP.
    Pediatr Infect Dis J; 2002 Feb 04; 21(2):133-8. PubMed ID: 11840080
    [Abstract] [Full Text] [Related]

  • 10. A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.
    Li L, Freed DC, Liu Y, Li F, Barrett DF, Xiong W, Ye X, Adler SP, Rupp RE, Wang D, Zhang N, Fu TM, An Z.
    NPJ Vaccines; 2021 Jun 02; 6(1):79. PubMed ID: 34078915
    [Abstract] [Full Text] [Related]

  • 11. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
    Wu K, Hou YJ, Makrinos D, Liu R, Zhu A, Koch M, Yu W-H, Paila YD, Chandramouli S, Panther L, Henry C, DiPiazza A, Carfi A.
    J Virol; 2024 Apr 16; 98(4):e0160323. PubMed ID: 38526054
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA, Lin L, Eckels KH, De La Barrera R, Dussupt V, Donofrio G, Sondergaard EL, Mills KT, Robb ML, Lee C, Adedeji O, Keiser PB, Curley JM, Copeland NK, Crowell TA, Hutter JN, Hamer MJ, Valencia-Ruiz A, Darden J, Peel S, Amare MF, Mebrahtu T, Costanzo M, Krebs SJ, Gromowski GD, Jarman RG, Thomas SJ, Michael NL, Modjarrad K.
    Lancet Infect Dis; 2023 Oct 16; 23(10):1175-1185. PubMed ID: 37390836
    [Abstract] [Full Text] [Related]

  • 13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W.
    Lancet Infect Dis; 2021 Jun 16; 21(6):803-812. PubMed ID: 33548194
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
    Vincenti F, Budde K, Merville P, Shihab F, Ram Peddi V, Shah M, Wyburn K, Cassuto-Viguier E, Weidemann A, Lee M, Flegel T, Erdman J, Wang X, Lademacher C.
    Am J Transplant; 2018 Dec 16; 18(12):2945-2954. PubMed ID: 29745007
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
    Jin Z, Wu J, Wang Y, Huang T, Zhao K, Liu J, Wang H, Zhu T, Gou J, Huang H, Wu X, Yin H, Song J, Li R, Zhang J, Li L, Chen J, Li X, Zhang M, Li J, Hou M, Song Y, Wang B, Gao Q, Wu L, Kong Y, Dong R.
    J Infect; 2023 Dec 16; 87(6):556-570. PubMed ID: 37898410
    [Abstract] [Full Text] [Related]

  • 19. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH, Levin MJ, Chatterjee A, Chakhtoura N, Takacs P, Catteau G, Dessy FJ, Moris P, Lin L, Struyf F, Dubin G, HPV-010 Study Group.
    Hum Vaccin Immunother; 2014 Dec 16; 10(12):3455-65. PubMed ID: 25483700
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.